Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS

WALTHAM, Mass., May 25, 2023 -- Apellis Pharmaceuticals, Inc. today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment of amyotrophic lateral... | May 25, 2023

Related Keywords

Australia ,Saudi Arabia ,Canada ,United States ,Jeffrey Eisele ,Meredith Kaya ,Lissa Pavluk ,National Institute Of Neurological Disorders ,Linkedin ,Twitter ,Nasdaq ,Exchange Commission On ,Apellis Pharmaceuticals Inc ,European Union ,Exchange Commission ,Combined Assessment ,Amyotrophic Lateral Sclerosis ,United Kingdom ,Forward Looking Statement ,Private Securities Litigation Reform Act ,Apelli Annual Report ,National Institute ,Neurological Disorders ,Amyotrophic Lateral Sclerosis Fact ,Retrieved June ,Apellis Pharmaceuticals ,Nc Stock Exchange ,News ,Information ,Press Release ,Bay ,023 ,Apellis ,Oday ,Nnounced ,Hat ,The ,Hase , ,Eridian ,Study ,Nvestigating ,Systemic ,Pegcetacoplan ,Or ,Treatment ,F ,Myotrophic Apls Us03753u1060 ,